Legal · Compliance
Compliance disclosures.
Motark's B2B-only trade posture, no-claims position, jurisdictional limitations, and counterparty obligations. Read alongside the operational detail on Operations & Compliance.
Last updated · 19 May 2026
01 · Trade posture
B2B counterparties, written contract, importer of record.
Three baseline principles that apply to every Motark engagement, irrespective of compound or destination.
01
B2B counterparties only
Motark supplies to ingredient distributors, supplement manufacturers, pharmaceutical and R&D partners. We do not sell to individual consumers and do not operate any retail channel.
02
Importer of record
Our manufacturing partners have an extensive network of logistical partners and can provide a full end-to-end service. Alternatively, the counterparty (you) may choose to be classified as the importer of record into the destination jurisdiction and bear responsibility for compliance with applicable import, customs, labelling, registration, and end-product claims requirements. Motark does not act as importer of record under any circumstance.
02 · Jurisdictions
Jurisdictional posture and limitations.
Active markets and the per-jurisdiction notes that govern what we supply and to whom. Per-compound regulatory status is also surfaced on each compound monograph.
Market
United States
Posture
Compounds with Dietary Supplement use cases are subject to the 21 CFR §111 framework. NDI notification status varies by compound and is communicated pre-supply; the counterparty is responsible for compliance in the destination market.
Market
European Union
Posture
Several compounds in Motark's register carry novel-food classification under Regulation (EU) 2015/2283. Where applicable, the counterparty is responsible for authorisation in the destination market.
Market
Restricted destinations
Posture
Motark will not supply where a destination jurisdiction prohibits the compound or where a destination requirement (labelling, certification, registration) cannot be met. This applies on a per-compound, per-destination basis.
03 · Claims
No health, therapeutic, or structure/function claims.
Motark's position on what the Site does — and does not — claim about its compounds.
01
No medical or therapeutic claims
Information published on this Site about compounds in Motark's register is technical, regulatory, and commercial reference material for B2B counterparties. Nothing constitutes a claim that any compound diagnoses, treats, cures, mitigates, or prevents any disease, in any jurisdiction.
02
Traditional-use and research context is historical
Where compound monographs reference traditional use or published research, this is for scientific and historical context. It does not constitute, and should not be read as, a nutritional, health, structure/function, or comparable claim about any product made with the compound.
03
Finished-product claims are the counterparty's responsibility
Counterparties who incorporate Motark compounds into finished products are solely responsible for the claims made on those products and for the regulatory pathway in the destination market. Motark does not approve, vet, or warrant counterparty claims.
04 · Reporting
Reporting concerns.
Three categories of concern we want to hear about, and how to surface them.
01
Compliance concerns
If you believe Motark or one of its partners has acted contrary to applicable regulation or to the posture set out on this page, please email the team. We treat such reports seriously and confidentially.
02
Suspected misuse of Motark identity
If you encounter a third party claiming to act on behalf of Motark — particularly in connection with payment instructions, banking details, or sample shipments — please verify directly with us before acting. We will not change banking details by email without prior signed counterparty notice.
03
Suspected counterparty misuse of supplied compound
Where a Motark-supplied compound is suspected of being diverted, mislabelled, or sold into a channel outside the counterparty contract, please contact the team. Investigations are conducted under NDA.